首页> 美国卫生研究院文献>Human Vaccines Immunotherapeutics >Two-tiered biological containment strategy for Lactococcus lactis-based vaccine or immunotherapy vectors
【2h】

Two-tiered biological containment strategy for Lactococcus lactis-based vaccine or immunotherapy vectors

机译:基于乳酸乳球菌的疫苗或免疫治疗载体的两级生物遏制策略

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The concept of biological containment was developed as a strategy to prevent environmental dissemination of engineered live vaccine or drug delivery vehicles. A mutation in the gene encoding thymidylate synthase (thyA), a key enzyme in the pyrimidine biosynthetic pathway, has previously been shown to limit growth of L. lactis vectors under restrictive conditions. We hypothesized that further mutations in the pyrimidine biosynthetic pathway might enhance the stability and safety of live L. lactis vectors. We show that a double mutation in the genes encoding ThyA and CTP synthase (PyrG) in L. lactis confers double auxotrophy for both thymidine and cytidine. However, the combination of two mutations failed to enhance the biological containment phenotype of the engineered strain. In the absence of thymine/thymidine, the thyA mutant exhibited a strong bactericidal phenotype. However, creation of the double mutant caused the loss of this phenotype, though survival in the mouse GI tract was enhanced. The implications for biological containment of live L. lactis based delivery vectors are discussed.
机译:开发生物围堵概念是为了防止工程活疫苗或药物输送工具在环境中传播。先前已显示出编码嘧啶生物合成途径中的关键酶胸苷酸合酶(thyA)的基因中的突变会限制乳酸乳球菌载体在限制性条件下的生长。我们假设嘧啶生物合成途径中的进一步突变可能会增强活乳球菌载体的稳定性和安全性。我们显示,在乳酸乳球菌中编码ThyA和CTP合酶(PyrG)的基因中的双重突变赋予胸苷和胞苷双重营养缺陷。但是,两个突变的组合不能增强工程菌株的生物遏制表型。在没有胸腺嘧啶/胸腺嘧啶核苷的情况下,thyA突变体表现出很强的杀菌表型。但是,尽管增加了小鼠胃肠道的存活率,但双突变体的产生导致该表型的丧失。讨论了基于活乳球菌的递送载体对生物遏制的意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号